Executive Director, Corporate Communications & Investor Relations
Current• Joined Executive Team in first quarter of 2024, focused on influencing cohesive leadership and effective top-down decision making that ensures company meets objectives.• Direct corporate communications strategy focused on protecting corporate reputation and positioning Aurinia as a leader in lupus nephritis with strong autoimmune pipeline potential. Activated a robust storytelling engine to elevate lupus nephritis (LN) within the lupus category and positioning medical, advocacy, and other Aurinia leaders as thought leaders in LN and autoimmune space.• Ensure all clinical, regulatory, and commercial milestones for Aurinia’s LN therapy, LUPKYNIS, are fully leveraged across external business and trade media, digital, and social channels and that LUPKYNIS is consistently positioned as the foundation therapy for LN.• Oversee internal communications strategy designed to ensure employees understand long-term company vision and strategy and to influence patient-centric culture with engaging communications that features people living lupus nephritis and Aurinia’s commitment to improving health outcomes.• Support the CEO and CFO in the development and execution of a comprehensive investor relations strategy tailored to Aurinia’s portfolio, stage of development, milestones, and trajectory.• Develop and lead quarterly earnings announcements, including messaging strategy, script for earnings calls, and analyst talking points. • Serve as a key point of contact for investors, sell-side analysts, and other members of the investment community, supporting the CEO and CFO in providing timely and accurate information.• Collaborate with cross-functional teams, e.g., medical, marketing, sales, legal, and finance, to develop investor-facing materials that showcase Aurinia’s strategy, portfolio, progress, and commercial potential.